DailyIQ
Last updatedjust now

ELV·Elevance Health, Inc.

$425.41
+3.32 (+0.79%)
Overnight$426.00+0.59 (+0.14%)
High
$433.89
Open
$427.00
Market Cap
90.23B
52W High
$447.88
Low
$420.99
P. Close
$425.41
P/E
18.18
52W Low
$274.84
Fwd P/E
14.37
DailyIQ Est.
$459.08
Inst. Ownership
45.8%
Short Interest
2.29%
Days to Cover
3.9
Div. Yield
1.61%
Next Ex-Div
~Dec 11
Div. Growth
14+ yrs
Technical Score (1D)
95
BULLISH
News Sentiment
69
BULLISH
On Oct 10, Elevance Health reported a 19.2% year‑to‑date gain, driven by recent Medicare product updates. The company announced plans to launch tailored Medicare Advantage offerings in 2027, aimed at simplifying member experience and supporting future profitability. Analysts noted that these developments highlight the company’s earnings potential. They questioned whether the current share price reflected that potential. The discussion centers on whether the stock’s valuation aligns with its earnings profile. The article underscores the importance of the Medicare updates for the company’s performance.
LOW TARGET
$393 -7.8%
2 analysts
MEAN TARGET
$452 +6.0%
17 analysts
HIGH TARGET
$492 +15.5%
12 analysts
PRICE RANGE
$393.00 - $492.00
SB / B / H / S / SS
7/12/10/1/1
DAILYIQ EST.
$459.08 (+7.8%)
Sector
Healthcare
Industry
Healthcare Plans
Exchange
NYQ
Country
United States
Symbol
ELV
Description
Elevance Health, Inc. is a leading U.S. health benefits company providing a diverse range of health plans and services. Operating through four key segments, the company serves a broad customer base, including individuals, employer groups, and government-sponsored programs like Medicare and Medicaid. Elevance Health's value proposition extends beyond traditional health insurance, encompassing pharmacy services, specialty insurance offerings, and a suite of healthcare-related services. These services include care management, virtual care options, and data analytics, all supported by its HealthOS platform and delivered under brands such as Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon. Formerly known as Anthem, Inc., the company's core mission is to provide comprehensive healthcare solutions, with its headquarters located in Indianapolis, Indiana.
Bought (1Y)
3,725 shares
$1.4M
Sold (1Y)
6,705 shares
$2.6M
Kaye MarkEVP & CFO
Award/Grant2,627 shares2026-10-02
Kaye MarkEVP & CFO
Tax Withholding4,161 shares2026-10-02
Wessling Erin MEVP & Chief Legal Officer
Tax Withholding255 shares2026-09-03
Craig Ryan REVP & Chief HR Officer
Tax Withholding144 shares2026-09-02
Wessling Erin MEVP & Chief Legal Officer
Tax Withholding94 shares2026-09-02
66/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
2.8%
Revenue CAGR
6.8%
Current Ratio
1.54x
Debt / Equity
0.73x
Return on Equity
12.9%
Earnings Summary
Elevance Health, Inc. operates as a leading U.S. health benefits provider, offering a broad array of health plans and services through its four key segments, including pharmacy, specialty insurance, and care management, all anchored by the HealthOS platform and delivered under brands such as Anthem Blue Cross and Blue Shield. The company serves individuals, employer groups, and government-sponsored programs, positioning it firmly within the competitive healthcare plans sector. In the most recent quarters, Elevance Health demonstrated a steady upward trajectory in revenue, rising from $44.99 billion in Q4 2024 to $49.41 billion in Q1 2026, and further to $49.83 billion in Q2 2026, reflecting a consistent year-over-year growth of roughly 10% across the same period. EPS, however, has shown more volatility: the company beat estimates in Q1 2025 (EPS $11.97 vs. $11.48) and Q1 2026 (EPS $12.58 vs. $6.29), while falling short in Q2 2025 (EPS $8.84 vs. $8.96) and Q3 2025 (EPS $6.03 vs. $4.94). This pattern indicates that while revenue growth remains robust, earnings per share can swing depending on cost dynamics or one‑off items. Historically, Elevance Health has maintained a positive YoY revenue trend, with the company consistently beating analyst expectations on revenue in the last four quarters, even when EPS misses occurred, underscoring a resilient top‑line performance. Recent news highlights a 19.2% year‑to‑date gain driven by Medicare product updates and the planned launch of tailored Medicare Advantage offerings in 2027, which analysts view as a potential catalyst for future earnings. Additionally, a recent Barclays upgrade to Overweight and a price target increase to $469 signal market confidence in the insurer’s growth prospects.

EPS

EstBeatMiss
$1.71$4.78$7.85$10.93$14.00Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$4.69 - -
Q2'26$5.07$7.45+47.0%
Q1'26$6.29$12.58+99.9%
Q4'25$3.13$3.33+6.5%
Q3'25$4.94$6.03+22.0%
Q2'25$8.96$8.84-1.4%

Revenue

EstBeatMiss
$47.6B$48.4B$49.1B$49.9B$50.7BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$49.7B - -
Q2'26$49.2B$49.8B+1.3%
Q1'26$48.0B$49.5B+3.2%
Q4'25$50.3B$49.3B-2.0%
Q3'25 - $50.1B -
Q2'25 - $49.4B -

Market Data

ELV Stock Snapshot

BULLISH95/100
$426.00+$0.59 (0.1%)
Market cap
90.23B
P/E ratio
18.2
Day range
$420.99 – $433.89
News sentiment
69/100 · Bullish
Analyst target
$451.71 (+6.0%)
Consensus
Buy · 31 analysts
52-week range+55.0% off low · -4.9% from high
$274.84$447.88
Price $426.00 DailyIQ Est. $459.08

The signal on ELV is bullish: price action is confirming the underlying trend, not fighting it. In Healthcare, names this size usually take direction from sector flows before company-level news.

Reverse DCF

What growth is priced into ELV?

RICH

At today's price, Elevance Health, Inc. needs to grow free cash flow about 12.7% a year for the next 10 years to justify its valuation at a 6.83% cost of capital. Over its actual history it has compounded free cash flow at 6.3% a year, so the market is asking for 6.3 percentage points above its own delivered rate. On that basis ELV looks priced above what its own growth record supports.

Implied FCF growth
12.7%
Historical FCF CAGR
6.3%
Growth gap
+6.3 pts
Verdict
RICH
Discount rate (WACC)
6.83%
Beta
0.54

Behaviour On Record

What ELV's own history says about today's numbers

Realized volatility (21d)
21.2% 30th pct
Below its peak
-26.8%
vs 200-day average
+12.7%
Up days (1y)
49%

Elevance Health, Inc. is currently running 21.2% annualised volatility over the last 21 sessions. Measured against ELV's own 13 years of daily returns rather than a market-wide average, that is the 30th percentile — on the quiet side for this stock, against a typical reading of 24.8%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ELV is trading -26.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -18.8%, and the deepest was -43.3% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +12.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 72nd percentile — a somewhat wider gap than its own norm. Over the past year ELV closed higher on 49% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, ELV finished the month higher 8 of 13 times, with a median return of +1.0% and an average of +2.7%. Its strongest month historically has been November at +5.6% on average, its weakest July at -2.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ELV has opened more than 2% away from the prior close in 101 of 3,266 sessions (3.1% of the time), with the largest gaps running +7.0% and -10.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, ELV moved an average of 3.5% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.8% and a largest of +5.5%.

All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against ELV's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ELV's sector?

Elevance Health, Inc. sits in the Health Care sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (improving).

Sector rank
#5 of 12
Sector state
Improving
Sector rotation score
64

Options Market

What is the options market pricing for ELV?

CallsPuts

For Elevance Health, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.00), with at-the-money implied volatility around 12.5%. The options market is pricing roughly a ±0.9% move by that expiry — a range of about $407.89–$415.51.

Put/call ratio (2026-10-16)
0.00
ATM implied volatility
12.5%
Total open interest
1
Expected move by 2026-10-16
±0.9% ($407.89–$415.51)

Analyst Rating Changes

Are analysts turning bullish or bearish on ELV?

Guggenheim most recently reiterated its rating on Elevance Health, Inc. to Buy on Oct 12, 2026 with a price target of $460 (from $455). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Guggenheim — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 12, 2026GuggenheimMaintainedBuy$455 → $460
Oct 7, 2026BarclaysMaintainedOverweight$457 → $469
Jul 17, 2026BernsteinMaintainedOutperform$482 → $488
Jul 17, 2026Leerink PartnersMaintainedMarket Perform$364 → $395
Jul 16, 2026RBC CapitalMaintainedSector Perform$439 → $424
Jul 16, 2026Wells FargoMaintainedOverweight$492 → $473
Jul 16, 2026GuggenheimMaintainedBuy$399 → $455
Jul 16, 2026BarclaysMaintainedOverweight$480 → $457
Jul 16, 2026BairdMaintainedNeutral$331 → $393
Jul 14, 2026TD CowenMaintainedBuy$400 → $465
Jul 14, 2026Truist SecuritiesMaintainedBuy$450 → $475
Jul 13, 2026Wells FargoMaintainedOverweight$391 → $492

Peers & ETF holders

ELV peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

69/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Guggenheim analyst Jason Cassorla maintained a Buy rating on Elevance Health (ELV) and increased the price target from $455 to $460. The upgrade reflects confidence in the company’s ongoing health‑care services strategy and expected earnings growth. The move signals a positive outlook for ELV’s valuation and may support investor sentiment.
What did this article say?
Elevance Health (ELV) attracted attention after its share price rose to $412.70, reflecting a 16.5% year‑to‑date gain. Analysts noted the company’s $201.1 billion annual revenue and a 19.16% one‑year total shareholder return, indicating solid momentum. A valuation model estimated a fair value of $451.38, suggesting the stock trades at a discount of roughly 9%. The analysis highlighted that the perceived undervaluation is based on earnings and margin assumptions rather than short‑term price movements.
What did this article say?
Elevance Health reported solid gains over the past year, driven by recent product updates in its Medicare business. The company announced plans for 2027 Medicare Advantage offerings aimed at providing more tailored support and a simplified member experience. These updates are expected to enhance future profitability and reinforce the durability of Elevance Health’s earnings base. The 19.2% return to shareholders underscores investor confidence in the company’s earnings profile. Overall, the developments suggest a positive trajectory for the firm’s financial performance.
What did this article say?
Elevance Health (ELV) posted an 11% year‑to‑date gain and trades below the healthcare sector’s average price‑to‑earnings ratio of 29.75, at less than 18 times trailing earnings. Analysts highlighted the company’s strong earnings outlook and the potential for institutional coverage to lift the stock further. The article frames ELV as an attractive buy for investors seeking undervalued healthcare exposure.
What did this article say?
Barclays analyst Andrew Mok upgraded Elevance Health to an Overweight rating on October 7, citing confidence in the company’s growth prospects. The firm increased its price target from $457 to $469, reflecting a bullish outlook on the insurer’s earnings trajectory. The upgrade signals a positive market view but does not indicate a transformative shift in the company’s fundamentals.
What did this article say?
The article compares Elevance Health (ELV) and Danaher (DHR) for value investors, noting ELV’s higher Zacks Rank of #2 versus DHR’s #3. ELV’s improving earnings outlook is highlighted by recent positive earnings estimate revisions. The analysis also references ELV’s favorable valuation metrics, such as its P/E ratio, supporting its attractiveness. Overall, the piece positions ELV as the more compelling value play in the medical services sector.
What did this article say?
Elevance Health scheduled the release of its third‑quarter 2026 financial results for October 21, 2026, followed by a management conference call and webcast the same morning. The call will provide an overview of the results and outlook, with dial‑in details and a live webcast link available to investors.
What did this article say?
Evercore ISI reduced its price target for Elevance Health (ELV) from $440 to $430 while maintaining an in‑line rating. The downgrade reflects a modest reassessment of the company’s valuation, though the overall outlook remains unchanged. The move signals a slight headwind for ELV’s stock, but does not alter the fundamental view of the business.
What did this article say?
Elevance Health (ELV) has seen a modest 8.9% year‑to‑date rise, reflecting a positive shift in analyst sentiment. The company’s full‑year earnings estimate was raised by 1.1% in the latest quarter, moving its Zacks Rank to a #2 (Buy) status. This upgrade signals growing confidence in ELV’s earnings outlook and positions the stock as a potential out‑performer within the broader medical sector.

Technical Analysis

Real-time indicators across multiple timeframes

95
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $35.69B combined position · 11 adding, 14 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy23,019,51810.87%$8.07B2026-01-29
BlackRock, Inc.▼ Sell18,991,0908.97%$7.34B2026-08-07
Wellington Management Group LLP▲ Buy9,213,5134.35%$3.56B2026-08-14
Geode Capital Management, LLC▼ Sell5,166,1242.44%$1.99B2026-08-12
Harris Associates L P▲ Buy4,924,5112.33%$1.90B2026-08-14
Artisan Partners Limited Partnership▼ Sell4,581,2222.16%$1.77B2026-08-13
Invesco Ltd.▼ Sell4,234,2312.00%$1.64B2026-08-14
Norges Bank▲ Buy3,958,8561.87%$1.53B2026-08-12
FMR LLC (Fidelity)▲ Buy3,131,6521.48%$1.21B2026-08-13
Morgan Stanley▼ Sell2,605,7641.23%$1.01B2026-08-13
Northern Trust Corp▼ Sell2,114,9861.00%$817.93M2026-08-13
Citigroup Inc▲ Buy2,096,8630.99%$810.92M2026-08-03
Goldman Sachs Group Inc▲ Buy2,005,6130.95%$775.63M2026-08-14
Bank of America Corp▼ Sell1,806,2670.85%$698.54M2026-08-14
Baillie Gifford & Co▼ Sell1,083,2370.51%$418.92M2026-08-06
JPMorgan Chase & Co▼ Sell997,2140.47%$386.95M2026-08-12
Ruane, Cunniff & Goldfarb L.P.▼ Sell979,5980.46%$378.84M2026-08-14
Citadel Advisors LLC▼ Sell906,3860.43%$350.53M2026-09-02
Millennium Management LLC▼ Sell727,5610.34%$281.37M2026-08-14
AllianceBernstein L.P.▼ Sell654,2490.31%$191.53M2026-08-14
AQR Capital Management LLC▲ Buy426,1600.20%$164.41M2026-08-14
Janus Henderson Group plc▲ Buy413,3490.20%$121.02M2026-05-18
Wells Fargo & Company▼ Sell302,2590.14%$116.89M2026-08-14
Renaissance Technologies LLC▲ Buy201,3730.10%$77.88M2026-08-13
Adage Capital Partners GP, L.L.C.▲ Buy170,6870.08%$66.01M2026-08-14
Q2 2026 flow:5.96M sh bought ($2.30B)4.53M sh sold ($1.75B)net +1.43M sh (+$554.40M)
Congressional Trading Activity
14 disclosed trades · ~$185.5K est. traded value · 7 buys, 7 sells
MemberChamberStateTypeAmountTradedFiled
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-08-132025-09-12
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-08-052025-09-12
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-07-102025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-242025-08-13
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-05-302025-06-06
Rob BresnahanHousePA08▼ Sell$15K - $50K2025-05-152025-05-31
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-04-292025-05-06
Dan NewhouseHouseWA04▼ Sell$1K - $15K2025-04-112025-05-16
Jared MoskowitzHouseFL23▼ Sell$1K - $15K2025-03-102025-04-08
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-02-242025-03-09
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-01-132025-02-13
Valerie HoyleHouseOR04▲ Buy$1K - $15K2024-10-292025-09-12